Compare Abeona Therapeutics Inc (ABEO) vs Fox Corp Class B (FOX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Fox Corp Class B — how do they compare? Abeona Therapeutics Inc trades at $6.71 (market cap $373.32M), while Fox Corp Class B trades at $48.35 (market cap $21.80B). The key difference: Fox Corp Class B is far larger — about 58.4× Abeona Therapeutics Inc's market cap, and Fox Corp Class B pays a 1.14% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | FOX | |
|---|---|---|
Market Cap | $373.32M | $21.80B |
Sector | Health | Media |
52-Week High | $7.23 | $67.76 |
52-Week Low | $4.17 | $44.39 |
Enterprise Value | $228.22M | $25.77B |
Dividend Yield | — | 1.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
FOX stock trades at $49.20, down 2.69% on the day, amid bearish technical signals and recent volatility following its $22 billion Roku acquisition announcement. The company shows strong fundamental performance with three consecutive quarterly earnings beats, revenue growth to $16.3 billion in 2025, and improved cash flow generation. However, technical indicators signal bearish momentum with the stock trading near support levels while analyst sentiment remains mixed with 43% buy ratings.
The outlook balances strong operational execution against acquisition integration risks. FOX's attractive valuation (P/E 13.14) and streaming expansion through Roku present growth opportunities, but high leverage and competitive pressures create near-term uncertainty. Investor focus remains on Q2 2026 earnings delivery and Roku synergy realization timelines.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Fox Corp Class B
Fox represents the assets not sold to Disney by the predecessor firm, Twenty First Century Fox. The remaining assets include Fox News, the FOX broadcast network, FS1 and FS2, Fox Business, Big Ten Network, 28 owned and operated local television stations of which 17 are affiliated with the Fox Network, and the Fox Studios lot. The Murdoch family continues to control the successor firm, which represents a large-scale bet on the value of live sports and news in the U.S. market.
Read more on FOX →
